Scott Braunstein - 11 Sep 2026 Form 4 Insider Report for AtaiBeckley Inc. (ATAI)

Reporting relationship: Director
Issuer ticker: ATAI
Reported as of: 11 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Sep 2026, 17:44:17 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ryan Barrett, as attorney in fact

Key filing fact

Scott Braunstein filed Form 4 for AtaiBeckley Inc. (ATAI) on 11 Sep 2026.

Key facts

This page summarizes Scott Braunstein's Form 4 filing for AtaiBeckley Inc. (ATAI).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 11 Sep 2026, 17:44.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643875 Primary reporting owner

Braunstein Scott

Relationship: Director
Address: C/O ATAI LIFE SCIENCES US, INC., C/O INDUSTRIOUS NYC, 250 WEST 34TH ST, NEW YORK
Signature: /s/ Ryan Barrett, as attorney in fact
Signature date: 11 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -206,000
Change %: -100%
Price
Shares after: 0
Date: 11 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 206,000
Exercise price: $1.34
Footnotes: F1, F2

ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -103,000
Change %: -100%
Price
Shares after: 0
Date: 11 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 103,000
Exercise price: $2.25
Footnotes: F2

ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -56,818
Change %: -100%
Price
Shares after: 0
Date: 11 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,818
Exercise price: $5.28
Footnotes: F2

ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -208,063
Change %: -100%
Price
Shares after: 0
Date: 11 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 208,063
Exercise price: $4.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Scott Braunstein is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

Footnote F2

At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).